common among persons whose ancestors hail from:
The exact number of people living with SCD in the U.S. is unknown. However, the CDC in collaboration with the National Institutes of Health and 7 states (California, Florida, Georgia, North Carolina, New York, Michigan and Pennsylvania) are coordinating the Registry and Surveillance System for Hemoglobinopathies (RuSH) project to learn about the number of people living with SCD and to better understand how the disease impacts their health. In Georgia, the Sickle Cell Foundation of Georgia, Inc. contributed as the outreach partner.
It is estimated that for Sickle Cell Disease (SCD) and Sickle Cell Trait (SCT):
People with SCD have less access to comprehensive team care than people with genetic disorders such as hemophilia and cystic fibrosis.
Sickle cell-related death among Black or African-American children younger than 4 years of age fell by 42% from 1999 through 2002. This drop coincided with the introduction in 2000 of a vaccine that protects against invasive pneumococcal disease.
During 2005, medical expenditures for children with SCD averaged $11,702 for children with Medicaid coverage and $14,772 for children with employer-sponsored insurance. About 40% of both groups had at least one hospital stay.